Page 42 - JCTR-11-3

Journal of Clinical and
Translational Research Immunogenicity and safety of flu vaccines

H1N1 vaccine: Randomized, observer-masked, single- South Korean subjects aged ≥65 years. Infect Chemother.
center clinical study. Results Immunol. 2012;2:184-189. 2018;50:301-310.
doi: 10.1016/j.rinim.2012.10.001 doi: 10.3947/ic.2018.50.4.301
19. Vesikari T, Ramsey K, Pitisuttithum P, et al. Repeated 29. Hartvickson R, Cruz M, Ervin J, et al. Non-inferiority of
exposure to an MF-59 adjuvanted quadrivalent subunit mammalian cell-derived quadrivalent subunit influenza
influenza vaccine (aQIV) in children: Results of two virus vaccines compared to trivalent subunit influenza
revaccination studies. Vaccine. 2020;38:8224-8231. virus vaccines in healthy children: A phase III randomized,
multicenter, double-blind clinical trial. Int J Infect Dis.
doi: 10.1016/j.vaccine.2020.10.036
2015;41:65-72.
20. Knuf M, Leroux-Roels G, Rümke HC, et al. Safety and
immunogenicity of an MF59-adjuvanted A/H1N1 pandemic doi: 10.1016/j.ijid.2015.11.004
influenza vaccine in children from three to seventeen years 30. Cruz-Valdez A, Valdez-Zapata G, Patel SS, et al.
®
of age. Vaccine. 2015;33:174-181. MF59-adjuvanted influenza vaccine (FLUAD ) elicits higher
immune responses than a non-adjuvanted influenza vaccine
doi: 10.1016/j.vaccine.2014.10.085
(Fluzone ): A randomized, multicenter, Phase III pediatric
®
21. Hoskins TW, Davies JR, Smith AJ, Miller CL, Allchin A. trial in Mexico. Hum Vaccin Immunother. 2018;14:386-395.
Assessment of inactivated influenza-A vaccine after three doi: 10.1080/21645515.2017.1373227
outbreaks of influenza A at Christ’s Hospital. Lancet.
1979;1:33-35. 31. Knuf M, Leroux-Roels G, Rumke HC, et al. Immunogenicity
and tolerability of an MF59-adjuvanted, egg-derived, A/
doi: 10.1016/s0140-6736(79)90468-9
H1N1 pandemic influenza vaccine in children 6-35 months
22. Jones-Gray E, Robinson EJ, Kucharski AJ, Fox A, Sullivan SG. of age. Pediatr Infect Dis J. 2014;33:e320-e329.
Does repeated influenza vaccination attenuate effectiveness? doi: 10.1097/INF.0000000000000462
A systematic review and meta-analysis. Lancet Respir Med.
2023;11:27-44. 32. Basu I, Agarwal M, Shah V, et al. Immunogenicity and safety
of two quadrivalent influenza vaccines in healthy adult and
doi: 10.1016/S2213-2600(22)00266-1
elderly participants in India - A phase III, active-controlled,
23. Trombetta CM, Gianchecchi E, Montomoli E. Influenza randomized clinical study. Hum Vaccin Immunother.
vaccines: Evaluation of the safety profile. Hum Vaccin 2022;18:1-10.
Immunother. 2018;14:657-670.
doi: 10.1080/21645515.2021.1885278
doi: 10.1080/21645515.2017.1423153
33. Diallo A, Victor JC, Feser J, et al. Immunogenicity and
24. Kim YH, Hong KJ, Kim H, Nam JH. Influenza vaccines: safety of MF59-adjuvanted and full-dose unadjuvanted
Past, present, and future. Rev Med Virol. 2022;32:e2243. trivalent inactivated influenza vaccines among vaccine-
naïve children in a randomized clinical trial in rural Senegal.
doi: 10.1002/rmv.2243
Vaccine. 2018;36:6424-6432.
25. Li Z, Zhao Y, Li Y, Chen X. Adjuvantation of influenza
vaccines to induce cross-protective immunity. Vaccines doi: 10.1016/j.vaccine.2018.08.032
(Basel). 2021;9:75. 34. Zhang Y, Wang Y, Jia C, et al. Immunogenicity and safety
of an egg culture-based quadrivalent inactivated non-
doi: 10.3390/vaccines9020075
adjuvanted subunit influenza vaccine in subjects ≥3 years:
26. Scheifele DW, McNeil SA, Ward BJ, et al. Safety, A randomized, multicenter, double-blind, active-controlled
immunogenicity, and tolerability of three influenza vaccines phase III, non-inferiority trial. Vaccine. 2022;40:4933-4941.
in older adults: Results of a randomized, controlled doi: 10.1016/j.vaccine.2022.06.078
comparison. Hum Vaccin Immunother. 2013;9:2460-2473.
35. Choi WS, Noh JY, Song JY, et al. Immunogenicity and safety
doi: 10.4161/hv.25580
of a cell culture-derived inactivated quadrivalent influenza
27. Beran J, Reynales H, Poder A, et al. Prevention of influenza vaccine (NBP607-QIV): A randomized, double-blind,
during mismatched seasons in older adults with an MF59- multi-center, phase III clinical trial in adults and elderly
adjuvanted quadrivalent influenza vaccine: A randomised, subjects. Hum Vaccin Immunother. 2017;13:1653-1660.
controlled, multicentre, phase 3 efficacy study. Lancet Infect
Dis. 2021;21:1027-1037. doi: 10.1080/21645515.2017.1297351
36. Bart S, Cannon K, Herrington D, et al. Immunogenicity
doi: 10.1016/S1473-3099(20)30694-0
and safety of a cell culture-based quadrivalent influenza
28. Yoo BW, Kim CO, Izu A, Arora AK, Heijnen E. Phase 4, vaccine in adults: A Phase III, double-blind, multicenter,
post-marketing safety surveillance of the MF59-adjuvanted randomized, non-inferiority study. Hum Vaccin Immunother.
influenza vaccines FLUAD and VANTAFLU in 2016;12:2278-2288.
®
®
Volume 11 Issue 3 (2025) 36 doi: 10.36922/JCTR025060006